Biocytogen signs agreement with Ona to develop ADCs targeting solid tumours
Under the terms of the agreement, Biocytogen will provide Ona with the opportunity to assess Biocytogen's proprietary fully…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
19 Dec 23
Under the terms of the agreement, Biocytogen will provide Ona with the opportunity to assess Biocytogen's proprietary fully…
19 Dec 23
Under the terms of the agreement, Lilly will remain the marketing authorisation holder and will produce migraine drugs…
19 Dec 23
Set-up of first BioNTainer as high-tech manufacturing solution for mRNA medicines is a critical step in establishing a…
18 Dec 23
The approval was based on the findings from the Phase 3 EV-302 in which the combination nearly doubled…
18 Dec 23
The collaboration between Revive and AMS aims to facilitate the transfer of technology for the lyophilized formulation of…
18 Dec 23
According to Arcutis Biotherapeutics, ZORYVE foam provides swift disease clearance and substantial itch reduction and is the first…
15 Dec 23
Teva will obtain exclusive worldwide rights to develop and commercialise Biolojic’s BD9, a multibody designed as a multi-specific…
15 Dec 23
FoundationOne CDx and FoundationOne Liquid CDx are the company’s tissue-based and liquid-based comprehensive genomic profiling tests
15 Dec 23
The approval is based on the results of a multi-site, single-arm, externally controlled trial in which the addition…
15 Dec 23
This Sciex quadrupole time-of-flight high-resolution mass spectrometer is dedicated to GLP/GCP quantitation of oligonucleotide therapeutics and the planned…